Premium
Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges
Author(s) -
Galanis E
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.211
Subject(s) - oncolytic virus , measles virus , bystander effect , virus , virology , measles , cancer therapy , cancer research , cancer , medicine , biology , immunology , vaccination
Measles virus (MV) is a negative‐strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics. Clinical Pharmacology & Therapeutics (2010) 88 5, 620–625. doi: 10.1038/clpt.2010.211